drugset
Drugs / 4-Demethyl-4-cholestryloxycarbonylpenclomedine
last change Aug 2020 re-read 3 minutes ago

4-Demethyl-4-cholestryloxycarbonylpenclomedine

Small molecule

Developed for
metastatic malignant neoplasm in the brain · primary brain neoplasm
Investigated by
DEKK-TEC, Inc. · Detroit Clinical Research Center · Icahn School of Medicine at Mount Sinai · National Cancer Institute (NCI) · Ochsner Health System · The University of Texas Health Science Center, Houston
+1 more · Tulane University

Trials 1

today NCT02038218 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT02038218 Sep 2013 → May 2016 metastatic malignant neoplasm in the brain, primary brain neoplasm DEKK-TEC, Inc. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 4-Demethyl-4-cholestryloxycarbonylpenclomedine ClinicalTrials.gov intervention name — accepted as the source's own label NCT02038218 ↗
Modality Small molecule “DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate” NCT02038218 ↗
Route Intravenous “treated every 21 days with a single infusion of DM-CHOC-PEN” NCT02038218 ↗